No statistically significant differences were observed between the rosuvastatin group and the combination therapy group in terms of age, sex distribution, history of hypertension, severity of coronary artery disease, HbA1c levels, fasting blood glucose (FBG), alanine aminotransferase (ALT), creatinine (Cr), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C levels, or preoperative left ventricular end-diastolic diameter (LVDD) and left ventricular ejection fraction (LVEF) (all P > 0.05). This evidence concerns the gene GPT and Hypertension.